Evommune (EVMN) Consolidated Net Income (2024 - 2026)

Evommune (EVMN) has 3 years of Consolidated Net Income data on file, last reported at -$21.7 million in Q1 2026.

• Consolidated Net Income for Q1 2026 came in at -$21.7 million, down 50.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$76.9 million (changed N/A YoY), and the FY2025 annual result was -$77.8 million, down 16.45% from the prior year.
• Consolidated Net Income improved to -$21.7 million in Q1 2026 per EVMN's latest filing, from -$28.3 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at -$12.5 million in Q3 2025 and troughed at -$28.3 million in Q4 2025.
• A 3-year average of -$18.9 million and a median of -$18.3 million in 2024 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2025 and 2026: Consolidated Net Income gained 21.62% in 2025, then slumped 50.18% in 2026.
• A 3-year view of Consolidated Net Income shows it stood at -$20.7 million in 2024, then sank by 36.41% to -$28.3 million in 2025, then climbed by 23.34% to -$21.7 million in 2026.
• Business Quant data shows EVMN's Consolidated Net Income at -$21.7 million in Q1 2026, -$28.3 million in Q4 2025, and -$12.5 million in Q3 2025.